Animal | NEFA (mg/dL) | Cholesterol (mmol/L) | HDL-c mmol/L | Triglycerides (mg/dL) | Plasma APOA1 (AU/L) | Hepatic Apoa1(RAU) |
|---|
Z | 39.1 ± 8.2 | 7.4 ± 0.6 | 5.4 ± 0.4 | 365 ± 202 | 0.64 ± 0.03 | ND |
ZDFV | 42.4 ± 20.0 | 7.2 ± 2.7 | 5.2 ± 1.9 | 1016 ± 654* | 0.90 ± 0.1* | 1.0 ± 0.4 |
ZDFT | 37.4 ± 16.7 | 7.1 ± 3.2 | 5.6 ± 2.5 | 1086 ± 388* | 0.78 ± 0.1 | 0.75 ± 0.2 |
ZDFD | 44.2 ± 6.1 | 3.1 ± 0.6*¶ | 2.4 ± 0.5*¶ | 516 ± 240¶ | 0.80 ± 0.06* | 0.7 ± 0.3¶ |
- Differences between non-diabetic and diabetic obese rats at the end of experimental interventions. Data are shown as mean ± SD. Statistically significant differences *p < 0.05 vs Zücker ¶p < 0.05 vs ZDFV. Hyperlipidaemia in all groups was mainly due to elevated triglycerides with modest increases in total cholesterol, particularly HDL cholesterol levels, with the exception of the low-calorie diet group (ZDFD) in which cholesterol was significantly less than the others. Fatty-diabetic rats showed higher APOA1 plasma concentration and hepatic mRNA expression than fatty-diabetic rats that were on low-calorie diet (ZDFD) or telmisartan treatment (ZDFT).
